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Abstract Our objective was to investigate the role of phos-
phodiesterase (PDE)3 and PDE4 and cGMP in the control of
cAMP metabolism and of phosphorylation of troponin I (TnI)
and phospholamban (PLB) when 5-HT4 receptors are activated
in pig left atrium. Electrically paced porcine left atrial muscles,
mounted in organ baths, received stimulators of particulate
guanylyl cyclase (pGC) or soluble guanylyl cyclase (sGC)
and/or specific PDE inhibitors followed by 5-HT or the
5-HT4 receptor agonist prucalopride. Muscles were freeze-
clamped at different moments of exposure to measure phos-
phorylation of the cAMP/protein kinase A targets TnI and PLB
by immunoblotting and cAMP levels by enzyme immunoas-
say. Corresponding with the functional results, 5-HT only
transiently increased cAMP content, but caused a less quickly
declining phosphorylation of PLB and did not significantly
change TnI phosphorylation. Under combined PDE3 and
PDE4 inhibition, the 5-HT-induced increase in cAMP levels
and PLB phosphorylation was enhanced and sustained, and
TnI phosphorylation was now also increased. Responses to
prucalopride per se and the influence thereupon of PDE3 and
PDE4 inhibition were similar except that responses were gen-
erally smaller. Stimulation of pGC together with PDE4 inhibi-
tion increased 5-HT-induced PLB phosphorylation compared
to 5-HT alone, consistent with functional responses. sGC
stimulation hastened the fade of inotropic responses to 5-HT,
while cAMP levels were not altered. PDE3 and PDE4 control
the cAMP response to 5-HT4 receptor activation, causing a
dampening of downstream signalling. Stimulation of pGC is
able to enhance inotropic responses to 5-HT by increasing
cAMP levels, while sGC stimulation decreases contraction to
5-HT cAMP independently.
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Introduction
5-HT4 receptors are Gs-protein-coupled receptors, which me-
diate a wide range of effects in various tissues triggered via
cAMP generation (Tonini 2005; Kaumann and Levy 2006;
Bockaert et al. 2011). In human and porcine atrium, 5-HT4
receptor activation by 5-HT promotes a transient increase in
inotropic and a more sustained increase in lusitropic effects
(Sanders and Kaumann 1992; De Maeyer et al. 2006). The
transient nature of the inotropic response is due to a rapid
degradation of the second messenger cAMP by phosphodies-
terases (De Maeyer et al. 2006). Phosphodiesterases are a
superfamily of cyclic nucleotide (cAMP or cGMP) hydrolysing
enzymes, and expression of PDE2, 3, 4 and 5 subtypes has
been reported in pig heart (Zimmermann et al. 1994; Jakobsen
et al. 2006). 5-HT4 receptor-mediated responses are controlled
predominantly by PDE3 in human and PDE3 and PDE4 in
porcine heart (Afzal et al. 2008; Galindo-Tovar et al. 2009).
The 5-HT4 receptor agonist prucalopride, which was approved
for use in Europe in 2009 and in Canada in 2011, for the
treatment of laxative-resistant chronic constipation, behaves
as a weak partial agonist in human and porcine heart, inducing
a very small inotropic response compared to the native agonist
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5-HT (Krobert et al. 2005; DeMaeyer et al. 2006). We recently
showed that these responses are also enhanced by and do not
fade under concomitant PDE3 and PDE4 inhibition in pig
atrium (Weninger et al. 2012).
Phosphodiesterases, in particular PDE3 and PDE2, can
mediate cross-talk between cAMP and cGMP signalling
pathways (Zaccolo and Movsesian 2007). PDE3 is specific
for cAMP and cGMP, but shows a much lower reaction
velocity for cGMP, resulting in a functional inhibition by
cGMP, while PDE2 shows dual specificity for both cGMP
and cAMP and is stimulated by cGMP (Fischmeister et al.
2006). cGMP production in the cell is catalysed by two
enzymes, a particulate guanylyl cyclase (pGC), which is
located in the plasma membrane and activated by natriuretic
peptides, and a nitric oxide (NO)-activated soluble guanylyl
cyclase (sGC) in the cytoplasm. Indeed, cAMP-mediated
responses to 5-HT4 receptor activation are influenced by
cGMP elevating agents. Afzal et al. (2011) reported that
both stimulation of pGC using C-type natriuretic peptide
(CNP) and sGC using the NO-donor Sin-1 increased inotro-
pic responses to 5-HT, presumably through inhibition of
PDE3, in failing rat heart. In a previous study, we showed
that pGC stimulation prolonged inotropic responses to 5-HT
in porcine atrium when PDE4 and PDE2 subtypes were
inhibited as well. We proposed that CNP increased cGMP
levels, thereby inhibiting PDE3, and this inhibition was
enhanced by preventing cGMP degradation by PDE2.
Because in pig atrium cAMP is controlled by PDE3 and
PDE4 in a redundant way, we also had to inhibit PDE4 to
unveil the effect of CNP. In contrast, activation of sGC
resulted in a hastened fading of the inotropic response to
5-HT in pig atrium (Weninger et al. 2012).
It has been demonstrated in human heart that activation of
β-adrenergic and 5-HT4 receptors increases phosphorylation
of the contractile proteins phospholamban (PLB) on Ser16 and
troponin I (TnI) on Ser23/24, through increased cAMP produc-
tion and a subsequent activation of protein kinase A (Bartel
et al. 1996; Gergs et al. 2009). Therefore, in this study, the role
of PDEs and pGC stimulation on 5-HT4 receptor-mediated
responses in pig left atrium was further investigated by mea-
suring the phosphorylation levels of these proteins as well as
tissue cAMP content in function of exposure time to 5-HT. The
effect of sGC activation on responses to 5-HT was studied by
measuring cGMP and cAMP content only.
Methods
Tissue preparation
The study was approved by the Ethical Committee for Animal
Experiments from the Faculty of Medicine and Health
Sciences at Ghent University. Adolescent male pigs (breed line
36, 10–12 weeks of age, 15–25 kg) were obtained from
Rattlerow Seghers N.V. (Lokeren, Belgium) and deeply
anaesthetized with an intramuscular injection of 5 ml Zoletil
100 (containing 250 mg zolazepam and 250 mg tiletamine)
from Virbac Animal Health (Carros, France). After exsangui-
nation, the heart was rapidly dissected and washed free of
blood in Krebs–Henseleit solution (composition in milli-
molar: glucose 11.1, CaCl2 2.51, NaHCO3 25, MgSO4 1.
18, KH2PO4 1.18, KCl 4.69, CaNa2-EDTA 0.033 and
NaCl 118). The left atrium was removed and placed in
fresh aerated buffer solution at room temperature. Left atrial
pectinate muscles (width, <2 mm; length, between 4 and
10 mm) were rapidly dissected, attached to tissue holders
(equipped with two electrodes designed for contact stimula-
tion) and put into 20 or 8 ml tissue baths filled with aerated
Krebs–Henseleit solution preheated to 37 °C. Eight muscle
strips were obtained per left atrium. To measure changes in
isometric force, Statham UTC2 force transducers (Gould,
Cleveland, OH, USA) and DBA 18 digital bridge amplifiers
(Anerma, Belgium) were used on a Powerlab data acquisition
system by ADInstruments (Spechbach, Germany) and
recorded with Chart v5.5.6 software (ADInstruments).
Electrical field stimulation was performed using a constant
voltage stimulator (Janssen Pharmaceutica, Beerse, Belgium).
Experimental protocols
Isometric force was calibrated in milli-newton (mN).
Resting load of left atrial pectinate muscles was set to 19.6
mN. Muscle contractions were stimulated with square-wave
pulses (0.5 Hz, 5 ms duration, 4 V). Muscle preparations
responding with a contraction below 4.9 mN were excluded.
During an equilibration time of 90 min, the buffer in the
organ bath was changed every 15 min. After equilibration,
(S)-(−)-propranolol (0.2 μM) and cocaine (6 μM) were
added to avoid β-adrenoceptor-mediated effects evoked by
the 5-HT-mediated release of noradrenaline and to inhibit
5-HT re-uptake by the cells, respectively (Kaumann 1990).
Tissues were allowed to stabilize for another 20 min before
the voltage was reduced to a value at which the generated
force was reduced to approximately half (between 2 and
4 V). Once a stable response was achieved, PDE inhibitors,
CNP or Sin-1 were added (details on drugs and concentra-
tions are given in the “Results” section). After an incubation
period of 30 min, 5-HT or the 5-HT4 receptor agonist
prucalopride were added in a concentration of 1 μM; this
concentration was selected on the basis of our previous
results (De Maeyer et al. 2006), where the maximal effect
was reached at this concentration in the presence of IBMX,
for both agonists. Two, 10 or 30 min after 5-HT4 receptor
stimulation, muscles were freeze-clamped in liquid N2 and
stored at −80 °C until further processing. In comparison,
muscles were also freeze-clamped in the absence of any
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compound (basal), and after incubating PDE inhibitors,
CNP or Sin-1 without addition of 5-HT4 receptor agonist.
Western blot analysis
Frozen tissues were homogenized using aMikro-dismembrator
U (B. Braun Biotech, Melsungen, Germany) and taken up in
10× volume/weight of buffer containing 7.5mMNaHCO3, 5%
SDS and 1 % phosphatase inhibitor cocktail 1 (Sigma-Aldrich,
Bornem, Belgium). This buffer was used to minimize dephos-
phorylation of proteins (Gergs et al. 2009). After an incubation
period of 30 min at room temperature, samples were
centrifuged (14,000×g for 10 min at room temperature), and
the supernatant was collected. Protein concentration was deter-
mined using the method of bicinchoninic acid (Thermo Fisher
Scientific, Aalst, Belgium). Twenty micrograms of protein
samples were separated on 4–12 % Bis-Tris Gels (Life tech-
nologies, Ghent, Belgium) and transferred to nitrocellulose
membranes. After blocking of the membrane in 5 % skim milk
for 1 h, primary antibody incubation was performed overnight
at 4 °C. Total and phosphorylated troponin I was detected using
anti-troponin I antibody 1:1,000 and anti-phospho-troponin I
Ser23/24 antibody 1:1,000 (Cell Signaling Technology, Boston,
MA, USA), respectively. Total and phosphorylated
phospholamban was detected using anti-phospholamban A1
antibody 1:10,000 and anti-phospholamban phospho-Ser16 an-
tibody 1:5,000 (Badrilla, Leeds, UK), respectively. All primary
antibodies were detected with an anti-rabbit HRP-linked sec-
ondary antibody 1:1,000 (Cell Signaling Technology), except
the anti-phospholamban A1 antibody, which was detected
using an anti-mouse HRP-linked secondary antibody 1:1,000
(Cell Signaling Technology). Secondary antibodies were in-
cubated for 1 h at room temperature. Immunological signals
were detected on Amersham Hyperfilm ECL (GE healthcare,
Diegem, Belgium) using Pierce® ECL (Thermo Fisher
Scientific) chemiluminescent substrate for total troponin I
and both phospholamban antibodies and SuperSignal®
WestFemto (Thermo Fisher Scientific) chemiluminescent sub-
strate for the phospho-troponin I Ser23/24 antibody. After de-
tection membranes were stripped for 45 min at 50 °C with a
buffer containing 2 % SDS, 62 mM Tris pH=6.8 and 0.8 %
β-mercaptoethanol, then washed extensively and blocked
again for 1 h in 5 % skim milk before incubation with a
primary antibody against β-tubulin 1:1,000 (Abcam,
Cambridge, UK). Films were scanned (hp scanjet 5590), and
signal intensities for total proteins and phosphorylated pro-
teins were analysed using ImageJ software, and the ratio with
β-tubulin, used as loading control, was calculated.
cAMP and cGMP content
Frozen tissues were homogenized using aMikro-dismembrator
U (B. Braun Biotech) and taken up in 10× volume/weight ice-
cold 6 % (w/v) trichloroacetic acid (TCA). After centrifugation
(2,000×g for 10 min at 4 °C), the supernatants were washed 3×
with 5 volumes of water-saturated diethyl ether to extract the
TCA from the sample. Briefly, diethyl ether was added, samples
were vortexed, ether and aqueous phases were allowed to sepa-
rate and the top ether layer was carefully removed using a
vacuum pump. After that, samples were dried in a warm water
bath at 60 °C under a stream of nitrogen, and the dried extract
was dissolved in buffer providedwith the cAMP and cGMPEIA
kits (Cayman Chemical, Tallinn, Estonia). cAMP or cGMP
content was detected following the manufacturer's instructions.
Absorbance at 405 nm was measured using a plate reader
(Amersham Biotrak II, GE healthcare). The pellet was dissolved
in 5 % sodium dodecyl sulphate (SDS) in 0.1 NNaOH and used
for protein quantification employing themethod of bicinchoninic
acid (Thermo Fisher Scientific). cAMP and cGMP concentra-
tions were expressed in picomoles per milligram protein.
Data analysis and statistics
Contraction force, maximal contraction velocity (+dF/dT)max
and maximal relaxation velocity (−dF/dT)max were analysed
based on isometric force measurements (mean of 10–15 con-
tractions) taken just before administration of PDE inhibitors,
CNP or Sin-1 (basal), then before addition of 5-HT or
prucalopride, and finally before the muscles were freeze-
clamped. Time to peak force (TPF) as well as time to 50 %
relaxation (TR50; mean of two contractions) was measured at
the same time points. Drug-induced increases or decreases in
cardiac parameters were expressed in percentage of basal
values.
All data are represented as means ± SEM of n=number of
pectinate muscles from different animals. Graph Pad Prism
V5.03 was used to draw graphs and to calculate the statistics.
Data in the presence of compound versus those in basal
conditions were compared with unpaired Student's t tests.
Differences between 5-HT4 receptor-mediated responses at a
given time of exposure to 5-HT in the absence and presence of
compounds were assessed using one-way ANOVA and
Bonferroni post-testing when more than two groups were
compared. A P value <0.05 was considered significant.
Drugs
EHNA hydrochloride, cilostamide, rolipram, C-type natriuretic
peptide (CNP) and amino-3-morpholinyl-1,2,3-oxadiazolium
chloride (Sin-1) were purchased at Tocris bioscience
(Huissen, The Netherlands). (S)-(−)-propranolol hydrochloride,
IBMX and serotonin creatinine sulphate salt monohydrate (5-
HT) were purchased at Sigma-Aldrich (Bornem, Belgium).
Cocaine hydrochloride was from Belgopia (Louvain-La-
Neuve, Belgium). Prucalopride succinate was a gift from
Shire-Movetis (Turnhout, Belgium). IBMX, cilostamide and
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rolipram were dissolved in dimethyl sulphoxide (DMSO). Sin-
1 was dissolved in Krebs–Henseleit solution. All other
chemicals were dissolved in deionized water. The DMSO
concentration in the organ baths did not exceed 0.1 %, which
by itself did not modify muscle contractions.
Results
Effect of PDE inhibition on cardiac responses, cAMP
generation and PLB and TnI phosphorylation by 5-HT
In concordance with our previous results (see DeMaeyer et al.
2006; Weninger et al. 2012), 5-HT (1 μM) caused a transient
increase in contraction force in pig left atrial preparations
(Fig. 1a). Inhibition of PDEs using the non-selective inhibitor
IBMX (20 μM) completely prevented the fade of the inotropic
response to 5-HT (Fig. 1b). PDE4 inhibition with rolipram
(1 μM) slightly increased and prolonged responses to 5-HT
(Fig. 1d). However, in muscles which were pre-treated for
30 min with the specific PDE3 and PDE4 inhibitors
cilostamide and rolipram, responses to 5-HT were increased,
and the fade of the response was completely abolished
(Fig. 1c), similar to responses in the presence of the non-
selective PDE inhibitor IBMX (Fig. 1b). The mean inotropic
responses are summarized in Fig. 2a, which shows the force
increase 30 min after addition of the PDE inhibitors and 2, 10
and 30 min after addition of 5-HT in the absence and presence
of PDE inhibition, in percentage of the basal contraction force.
The decrease in time to peak force (TPF) as well as time to
50 % relaxation (TR50) in percentage of basal values is given
in Fig. 2c, d. Absolute force as well as (+dF/dt)max (maximal
contraction rate) and R2 values [obtained by dividing the
maximal contraction rate (dF/dt)max by the maximal relaxation
rate (dF/dt)min] is listed in Online resource 1. Basal TPF and
TR50 values were similar between groups. TPF and TR50 were
both clearly decreased by IBMX as well as by cilostamide
plus rolipram (Fig. 2c, d), e.g. TPF from 53.4±3.4 to 47.8±
1.5 ms and TR50 from 41.8±1.3 to 34.2±1.3 ms (n=5) by
30 min incubation with cilostamide plus rolipram. 5-HT de-
creased TPF to −11±1 % below basal at 2 min (Fig. 2c).
Unlike contraction force, this decrease in TPF did not fade
(−9±5 % below basal at 30 min). With pre-incubation of
IBMX or cilostamide and rolipram, the decrease in TPF by
5-HT was significantly enhanced (to about −20 % below
basal, P<0.05) and was also maintained for 30 min. 5-HT
decreased TR50 2 min after addition to the same extent as TPF
(about −10 % below basal), but TR50 showed a further de-
crease after 10 min to −22±6 % where it stabilized (Fig. 2d).
With PDE inhibition using IBMX or cilostamide and
rolipram, the decrease in TR50 by 5-HT was significantly
enhanced (to −35±3 % and −32±3 % at 2 min, respectively,
P<0.05) and remained at that level after 10 and 30 min.
At the same time points where force of contraction was
measured, the muscles were freeze-clamped, and cAMP con-
tent (not tested 30 min after addition of 5-HT) as well as
phosphorylation of PLB at Ser16 and TnI at Ser23/24 was
detected. Total PLB and TnI levels were also measured but
were not changed by any compounds tested (representative
blots are shown in Fig. 2e, f). The influence of PDE inhibition
per se using IBMX, or concomitant cilostamide plus rolipram
on basal muscle contractility, cAMP levels and the degree of
PLB and TnI phosphorylation were minor; the increases of
functional responses and PLB phosphorylation by IBMX as
well as the small increase in TnI phosphorylation by concur-
rent cilostamide and rolipram reached statistical significance.
5-HT significantly increased tissue cAMP content to about
1.5-fold 2 min after addition (P<0.05), while after 10 min,
cAMP levels had almost returned to basal (Fig. 2b), which is
in accordance to the contractile response (Fig. 2a). In the
presence of cilostamide and rolipram, 5-HT increased cAMP
levels three- and four-fold, 2 and 10 min after its addition,
respectively; this was significantly different from 5-HT alone
(P<0.05; Fig. 2b). Phosphorylation of PLB on Ser16 was
increased four-fold in muscles freeze-clamped 2 min after
addition of 5-HT (P<0.05; Fig. 2e). Dephosphorylation
appears to be slower than the fade of the inotropic response
(Fig. 2a) because 10 and 30 min after adding 5-HT, phosphor-
ylation of PLB was still significantly increased by about
four- and two-fold, respectively, compared to basal (P<0.05;
Fig. 2e). With concomitant PDE3 and PDE4 inhibition, 5-HT
increased phosphorylation of PLB approximately six-fold
versus basal, and protein phosphorylation did not decrease
over the 30 min tested; this was significant compared to 5-HT
alone (P<0.05). The same response was observed for PDE
inhibition using the non-selective PDE inhibitor IBMX, which
also showed a stable approximately six-fold increase in PLB
phosphorylation (Fig. 2e). The change in TnI phosphorylation
by 5-HT at 2 min from 0.6 to 1.0 did not reach significance
(Fig. 2f). Under PDE inhibition with IBMX or cilostamide
plus rolipram, TnI phosphorylation after 5-HT was signifi-
cantly increased three to four-fold compared to basal (Fig. 2f).
Effect of PDE inhibition on cardiac responses, cAMP
generation and PLB and TnI phosphorylation by the 5-HT4
receptor agonist prucalopride
As observed before (see Weninger et al. 2012), contractile
responses to prucalopride (1 μM; Fig. 3a) in porcine left
atrium were considerably smaller than responses to 5-HT
showing a maximal increase of only 17 % above basal
compared to 98 % for 5-HT (see Fig. 2a). Interestingly,
TPF and TR50 showed a maximal decrease in response to
prucalopride of −10 % and −18 % below basal, respectively
(Fig. 3c, d), which is similar as with 5-HT (compare with
Fig. 2c, d). Responses to prucalopride developed slower
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than responses to 5-HT, showing maximal force increase
10 min after addition and maximal decrease of TPF as well
as TR50 only at 30 min. As seen with 5-HT, contraction
force faded with time and even decreased below basal after
30 min (Fig. 3a), while TPF continually decreased over the
30 min measured (Fig. 3c), and TR50 strongly decreased
from 2 to 10 min and then stabilized (Fig. 3d). Pre-
incubation of muscles with IBMX (20 μM) or concomitant
cilostamide (0.3 μM) and rolipram (1 μM) significantly
further increased contraction force in response to
prucalopride compared to prucalopride alone; these re-
sponses did not fade over the observed period of 30 min
(Fig. 3a; Weninger et al. 2012). The decrease in TPF by
prucalopride developed faster and was more pronounced
under PDE inhibition with IBMX or cilostamide plus
rolipram, being stable at approximately −20 % from 2 to
30 min (Fig. 3c). The same was observed for the decrease in
TR50 (approximately −30 % from 2 to 30 min; Fig. 3d).
cAMP content did not significantly increase after addition of
prucalopride alone. Only when PDE3 and 4 were inhibited
using cilostamide plus rolipram, cAMP content was signifi-
cantly increased by about 1.5- and 2-fold, 2 and 10 min after
addition of prucalopride, respectively (P<0.05; Fig. 3b).
Prucalopride increased PLB phosphorylation two-fold
10 min after its addition (P<0.05; Fig. 3e), but not at 2 and
30 min. Phosphorylation of PLB in response to prucalopride
was increased five-fold compared to basal in the presence of
IBMX (P<0.05) and concomitant cilostamide and rolipram
(P<0.05), which was significantly higher versus prucalopride
alone at some time points. The results for the phosphorylation
state of TnI were less clear. A significant increase in TnI
phosphorylation was observed 2 and 30 min after addition of
prucalopride alone (P<0.05; Fig. 3f). With PDE inhibition,
phosphorylation of TnI in response to prucalopride increased
slowly, reaching a maximal increase (three-fold for IBMX and
five-fold for cilostamide and rolipram) 30 min after addition of
prucalopride. These increases in TnI phosphorylation at
30 min, however, were not significantly different from re-
sponses to prucalopride in the absence of PDE inhibition.
Effect of particulate guanylyl cyclase activation on inotropic
responses, cAMP generation and PLB and TnI
phosphorylation by 5-HT
Tissue cGMP content was increased about two-fold (P<0.05,
n=5; Fig. 4) in muscles freeze-clamped 2 min after addition of
CNP, confirming that CNP indeed stimulates cGMP produc-
tion. However, 30 min after incubation of CNP, cGMP was
not higher than basal cGMP levels (Fig. 4). As reported before
(Weninger et al. 2012), CNP alone did not affect inotropic
responses to 5-HT (data not shown). PDE4 inhibition using
rolipram (1 μM) increased and prolonged the inotropic re-
sponse mediated by 5-HT, showing a contraction force of
61 % above basal at 10 min, compared to 7 % above basal
10 min after addition of 5-HT in the absence of the PDE
inhibitor (Fig. 1d and 5a; Weninger et al. 2012). CNP and
rolipram administered together showed a further enhancement
of inotropic responses to 5-HT to 113 % above basal at
10 min (Fig. 1e and 5a); this was not further enhanced in
the additional presence of 10 μM of the PDE2 inhibitor
EHNA (115 %; Fig. 5a). We also noticed that CNP had a
small inotropic effect of its own (Fig. 5a), which was
enhanced when rolipram was administered together with
CNP (Fig. 1e, f and 5a).
Tissue cAMP content was increased 2 min after addition
of CNP (P<0.05) and after simultaneous addition of CNP
and rolipram (P=0.06; Fig. 5b). Tissue cAMP content in
response to 5-HT was significantly increased by about two-
fold compared to basal levels 10 min after administration in
muscles receiving rolipram, and concomitant rolipram plus
Rolipram
5 min
Rolipram+CNP
5 min
Rolipram+CNP+
EHNA
5 min
5mN 
5mN 
5-HT
5 min 5 min
5-HT
5-HT5-HT
5-HT
5-HT
IBMX
5 min
a b c
d e f
Cilostamide+
Rolipram
Fig. 1 Representative tracings from electrically paced porcine left
atrial pectinate muscles showing the responses to 1 μM 5-HT alone
(a) or in the presence of PDE inhibition using IBMX (20 μM) (b) and
concomitant cilostamide (0.3 μM) plus rolipram (1 μM) (c). The lower
traces show representative responses to 5-HT in the presence of
rolipram (d), rolipram plus C-type natriuretic peptide (CNP, 0.3 μM)
(e) and rolipram plus CNP plus the PDE2 inhibitor EHNA (10 μM) (f).
Ten minutes after addition of 5-HT, the traces end because at this time
point, the muscles were freeze-clamped for biochemical analysis
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CNP (P<0.05). In the presence of the three compounds
rolipram, CNP and EHNA, cAMP content in response to
5-HTwas increased three-fold, which was significant versus
5-HT in the absence of these compounds (P<0.05; Fig. 5b).
PLB phosphorylation essentially mirrored the functional
effects depicted in Fig. 5a. Phosphorylation of PLB was
increased two-fold (P<0.05) after the simultaneous addition
of CNP and rolipram (Fig. 5c). PLB phosphorylation was
not significantly increased 10 min after addition of 5-HT in
this set of experiments, while there was significant phos-
phorylation in the same condition in the set of experiments
depicted in Fig. 2e. In the presence of rolipram, PLB phos-
phorylation was increased four-fold 10 min after addition of
5-HT (P<0.05; Fig. 5c). The combinations of rolipram plus
CNP, and rolipram plus CNP plus EHNA, both increased
PLB phosphorylation in response to 5-HT about six-fold
(P<0.05 versus basal; Fig. 5c); however, this was not sig-
nificant versus 5-HT in the presence of rolipram alone. TnI
phosphorylation showed the same tendencies as PLB phos-
phorylation, but the effects were less pronounced (Fig. 5d).
Phosphorylation of TnI was increased 1.5 times 2 min after
the simultaneous addition of CNP and rolipram (P<0.05;
Fig. 5d), while no significant effect was observed with CNP
alone. Ten minutes after administration of 5-HT, TnI phos-
phorylation was not significantly increased, while in the
presence of rolipram, rolipram plus CNP and the triple
combination rolipram plus CNP plus EHNA, the phosphor-
ylation level of TnI was increased by about two to three-fold
versus basal (P<0.05; Fig. 5d); however, no significance
was observed when compared to the condition with 5-HT
alone.
Effect of soluble guanylyl cyclase activation on inotropic
responses and cAMP generation by 5-HT
Sin-1 (300 μM) alone significantly decreased muscle con-
tractility to −34 % below basal (P<0.05; Fig. 6c). 5-HT
could still increase muscle contractility to 56 % above basal
2 min after its addition in the presence of Sin-1 (300 μM),
which was not significantly different from responses to
5-HT in the absence of Sin-1. Ten minutes after addition
of 5-HT, force increase had decreased to −26 % below basal
in the presence of Sin-1, while remaining 3 % above basal in
the absence of the drug (Fig. 6c; Weninger et al. 2012).
Sin-1 increased tissue cGMP content massively by 30-fold
(P<0.05; Fig. 4), confirming that production of cGMP is
stimulated. Interestingly, also cAMP content was increased
by about 1.5-fold after administration of Sin-1 (P<0.05;
Fig. 6d). 5-HT in the presence of Sin-1 significantly increased
tissue cAMP content 2 min after addition (P<0.05), while
after 10 min, cAMP levels had almost returned to basal; these
responses were similar to cAMP levels observed with 5-HT in
the absence of Sin-1.
Discussion
The aim of this study was to further investigate the role of
PDEs and cGMP in the control of the response to 5-HT4
receptor stimulation in porcine left atrium by analysing the
concentration of cAMP and the degree of phosphorylation
of phospholamban (PLB) and troponin I (TnI). Both pro-
teins have a direct role in the establishment of the functional
response, and activation of human cardiac 5-HT4 receptors
has been correlated with their phosphorylation (Gergs et al.
2009). TnI is a member of the troponin protein complex of
the contractile machinery in the cell, which upon phosphor-
ylation decreases myofibrillar Ca2+ sensitivity, resulting in a
faster relaxation, thus a lusitropic response (Matsuba et al.
2009). PKA phosphorylation of PLB Ser16 causes the pro-
tein to release its inhibition on SERCA, the sarcoplasmic
reticulum (SR) Ca2+ pump, thereby allowing a faster re-
uptake of Ca2+ into the SR. This allows for a faster clearance
of Ca2+ from the myoplasm during diastole augmenting
relaxation and increases Ca2+ in the SR to be released during
the next systole which increases contraction (MacLennan
and Kranias 2003). Another SR protein, the type 2
ryanodine receptor Ca2+ channel, is also phosphorylated
by PKA, which increases its sensitivity to Ca2+-induced
activation enhancing cardiac contraction (Marx et al. 2000).
Influence of PDE3 and PDE4 on the signal transduction
pathway of 5-HT4 receptor stimulation
In human right atrium, the inotropic response to 5-HT
(2 μM) was stable 7 min after its addition; at this moment,
the cAMP content and the phosphorylation of PLB and TnI
were increased 2.8-, 1.7- and 1.5-fold (Gergs et al. 2009). In
Fig. 2 Effect of 5-HT (1 μM) alone or in the presence of PDE inhibition
with IBMX (20 μM) or cilostamide (0.3 μM) plus rolipram (1 μM) on
force of contraction (a), tissue cAMP content (b), time to peak force
(TPF) (c), time to 50 % relaxation (TR50) (d), phosphorylation of
phospholamban (e) and phosphorylation of troponin I (f) of n=3 to 5
(c, d), n=5 (a, e, f) and n=6 (b) electrically paced porcine left atrial
pectinate muscles. On the x-axis, the different conditions are plotted;
basal values were taken before addition of any compounds; IBMX and
C+R show values 30 min after addition of IBMX and cilostamide plus
rolipram, respectively; all other bars depict responses to 5-HT either
2 min (2′), 10 min (10′) or 30 min (30′) after its administration, in the
absence (5-HT) or presence of IBMX (IBMX 5-HT) or cilostamide plus
rolipram (C+R 5-HT). Force of contraction as well as TPF and TR50 was
calculated in percentage to basal values (a, c, d), cAMP content is shown
as picomole cAMP per milligram protein (b) and phosphorylation of
phospholamban on Ser16 (e) and troponin I on Ser23/24 (f) is expressed
relative to the household protein β-tubulin [representative western
?blots are inserted in panels e and f showing phosphorylated protein
(PLB Ser16, TnI Ser23,24) and total protein (PLB total, TnI total)].
*P<0.05 versus basal, unpaired t test; ΔP<0.05 for 5-HT in the presence
of IBMX or C+R versus 5-HT in their absence, one-way ANOVAwith
Bonferroni post-testing
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the actual study in porcine left atrium, the inotropic response
to 5-HT (1 μM) peaked at 2 min after its addition, and the
cAMP content and PLB phosphorylation were significantly
increased at this time point, while TnI phosphorylation was
not. At 10 and 30 min after administration of 5-HT, the
inotropic response had declined to a very moderate level
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above basal corresponding with a no longer increased cAMP
level. However, the degree of PLB phosphorylation remained
increased at 10 and 30min after addition of 5-HT. There was a
clear tendency to increased TnI phosphorylation by 5-HT
which was persistent over the 30-min observation period. It
was shown before that in isolated rabbit and guinea pig hearts,
TnI phosphorylation persists, while PLB phosphorylation re-
verses within 15 min afterβ-agonist withdrawal (Garvey et al.
1988; Stemmer et al. 2000). These data are mostly in line with
our results, except for the dephosphorylation velocity of PLB.
However, caution should be taken when comparing dephos-
phorylation rates of PLB and TnI, observed after β-agonist
withdrawal, to the results here since we studied PLB and TnI
phosphorylation in response to continued stimulation with
5-HT. Sustained TnI and PLB phosphorylation could be due
to limited access by protein phosphatases (PP) or continued
phosphorylation by PKA. PLB and TnI have been reported to
be dephosphorylated by PP1 and PP2Awhich, like PKA, are
tightly regulated and compartmentalized by binding to scaf-
folding proteins (Redden and Dodge-Kafka 2011). Taken
together, our results suggest that the inotropic mechanisms
initiated by 5-HT fade quickly with the decline in cAMP,
while the lusitropic effects are sustained as also reported in
DeMaeyer et al. (2006), due to maintained phosphorylation of
TnI and PLB. The strong further decrease of TR50 from 2 to
10 min is also indicative of a maintained lusitropic effect.
Prucalopride behaves as a partial 5-HT4 receptor agonist in
porcine left atrium, inducing slower and weaker inotropic
responses than 5-HT (Weninger et al. 2012). This was con-
firmed in the actual study showing a mild but significant
inotropic response at 2 and 10 min after addition of
prucalopride. Interestingly, prucalopride decreased both TPF
and TR50 to about the same level as 5-HT, but decreases
developed slower. As seen for 5-HT, we observed a strong
further decrease in TR50 from 2 to 10 min after addition of
prucalopride. This suggests that lusitropic responses to
prucalopride develop slower but are equally well developed
compared to 5-HT. Prucalopride induced increased phosphor-
ylation of TnI and PLB, which was well maintained for TnI
corresponding with a sustained lusitropic effect. The cAMP
level in response to prucalopride was not increased at any time
point, suggesting that whole tissue cAMP analysis cannot
detect the small and possibly highly compartmentalized
cAMP increase induced by the partial agonist prucalopride.
In the left atrium of adolescent pigs, it was previously
shown that single inhibition of PDE3 only slightly increases
responses to 5-HT but does not prevent the fade, while
single PDE4 inhibition causes a small increase and prolon-
gation (Weninger et al. 2012), the latter also being con-
firmed in the actual study. However, concomitant PDE3
and PDE4 inhibition completely prevents the fade of the
response to 5-HT and induces a clearly more pronounced
and sustained response to the 5-HT4 receptor agonist
prucalopride (Galindo-Tovar et al. 2009; Weninger et al.
2012). This was confirmed in the actual study, now also
showing that combined PDE3 and PDE4 inhibition largely
increased and sustained cAMP levels after addition of 5-HT,
corroborating a redundant control by PDE3 and PDE4 of the
cAMP response to 5-HT. Combined PDE3 and PDE4 inhi-
bition also led to increased levels of cAMP after addition of
prucalopride; although the cAMP levels obtained were
clearly lower than with 5-HT, this is sufficient to drive the
inotropic response to prucalopride to a comparable degree as
with 5-HT. Probably a certain amount of cAMP is sufficient
to induce the maximal achievable contractile response with-
in the tissue, as also illustrated by the fact that the cAMP
content 2 min after addition of 5-HT is strongly increased in
the presence of concurrent cilostamide and rolipram com-
pared to that in their absence, while the increase in PLB and
TnI phosphorylation is less pronounced, and the functional
responses are almost the same at this time point (Fig. 2a, b).
It was found before that pronounced β-adrenergic stimula-
tion or moderate β-adrenergic stimulation combined with
PDE inhibition causes excessive levels of cAMP in cardiac
myocytes but fails to show equivalent increases in contrac-
tion responses (Xiang et al. 2005; De Arcangelis et al.
2008). This discrepancy can be explained by increased
protein phosphatase (PP) activity in response to high levels
of cAMP, which prevents a hyperphosphorylation of PKA
target proteins and consequentially limits contraction re-
sponses (De Arcangelis et al. 2008). Phosphorylation of
PLB and TnI in response to 5-HT and prucalopride is
increased to the same extent under general PDE inhibition
with IBMX and under combined PDE3 plus PDE4 inhibi-
tion, further illustrating that these two PDE subtypes main-
tain a tight control on the cAMP response to 5-HT4 receptor
activation. Decreases in TR50 as well as TPF in response to
5-HT4 receptor stimulation are both significantly larger un-
der PDE inhibition using IBMX or concomitant cilostamide
and rolipram, indicating an enhanced lusitropic effect. This
is supported by the increased and sustained phosphorylation
Fig. 3 Effect of prucalopride (Pru, 1 μM) alone or in the presence of
PDE inhibition with IBMX (20 μM) or cilostamide (0.3 μM) plus
rolipram (1 μM) on force of contraction (a), tissue cAMP content (b),
TPF (c), TR50 (d), phosphorylation of phospholamban (e) and phos-
phorylation of troponin I (f) of n=3 to 5 (c, d), n=5 (a, e, f) and n=6
(b) electrically paced porcine left atrial pectinate muscles. See legend
in Fig. 2 for detailed explanation of the different conditions depicted on
the x-axis of the graphs and the way of expressing the results. *P<0.05
versus basal, unpaired t test; ΔP<0.05 for Pru in the presence of IBMX
or C+R versus Pru in their absence, one-way ANOVAwith Bonferroni
post-testing
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of the regulatory proteins TnI and PLB in these conditions.
The further decrease in TR50 from 2 to 10 min after 5-HT4
receptor stimulation (see Fig. 2d and 3d) was not observed
in the presence of PDE inhibition. Possibly the maintained
inotropic response under PDE inhibition, due to preserva-
tion of cAMP levels, prevents a further decrease in relaxa-
tion time.
Influence of cGMP generated by sGC and pGC on basal
muscle function and on the response to 5-HT
Both C-type natriuretic peptide (0.3 μM) and the NO-donor
Sin-1 (300 μM) significantly increased tissue cGMP content
by about 2- and 30-fold, respectively (Fig. 4). The influence
on basal muscle contractility and on the inotropic response
to 5-HT however is different.
CNP transiently increases basal muscle contractility, while
Sin-1 continuously decreases it (Figs. 5a and 6b; Weninger et
al. 2012). Both effects have been observed before and were
reported to be mediated by protein kinase G I (PKG; Layland et
al. 2005). Like cAMP signalling, cGMP signalling is highly
compartmentalized, and pGC and sGC increase cGMP close to
the plasma membrane and in the bulk cytosol, respectively,
thereby activating different subsets of PKG (Castro et al. 2006);
this might explain the differential effects of CNP and Sin-1 on
basal muscle contractility. The transient inotropic response to
CNP was augmented in the presence of PDE4 inhibition
(Weninger et al. 2012; Fig. 5a). In the literature, both a negative
inotropic response and a biphasic response to CNP consisting
of an initially positive inotropic and lusitropic response
followed by a negative inotropic effect are described (Brusq
et al. 1999; Pierkes et al. 2002; Qvigstad et al. 2010). The
suggested mechanism is a cGMP/PKG-mediated phosphoryla-
tion of phospholamban and troponin I. Indeed, PLB on Ser16
and troponin I on Ser23/24 are phosphorylated by PKG with
rates similar to that of PKA and about 100-fold slower than that
of PKA, respectively (Raeymaekers et al. 1988; Matsuba et al.
2009). In accordance to that, in our study, CNP tended to
increase phosphorylation of PLB and TnI, reaching signifi-
cance in the concomitant presence of the PDE4 inhibitor
rolipram (Fig. 5c, d). We have no clear-cut explanation for the
additional effect of PDE4 inhibition, since PDE4 is strictly
cAMP specific and the effect of CNP has always been reported
to be mediated by cGMP (Brusq et al. 1999; Layland et al.
2002; Pierkes et al. 2002; Su et al. 2005); to our knowledge,
non-specific effects of rolipram not related to PDE inhibition
have not been reported. A cross-talk between cGMP and cAMP
signalling might be involved possibly through inhibition of
PDE3 by CNP-generated cGMP (see below). We indeed ob-
served a small but significant increase in cAMP content in
response to CNP. This is in contrast to reports in rodent hearts
where CNP increased cGMP but did not change cAMP levels
(Brusq et al. 1999; Pierkes et al. 2002). Surprisingly, Sin-1 also
slightly increased cAMP levels, which is in contrast to a study
in guinea pig myocytes, where 500 μM of the NO-donor did
not significantly modify cAMP (Malan et al. 2003).
As observed before (Weninger et al. 2012), CNP and Sin-
1 also had a differential effect on the inotropic response to 5-
HT, Sin-1 hastening its fade while CNP plus rolipram re-
duced the fade. An influence of elevated cGMP on cAMP
signalling, predominantly mediated by phosphodiesterases 2
and 3, has been reported (Mery et al. 1993; Zaccolo and
Movsesian 2007). PDE2 is specific for both cAMP and
cGMP, but its cAMP-degrading activity is stimulated by
cGMP. In the presence of increased cGMP, PDE2 signifi-
cantly contributes to cAMP degradation and blunting of
β-adrenergic receptor-mediated inotropic effects in mouse
and rat cardiomyocytes (Mongillo et al. 2006). PDE3 also
has cGMP and cAMP degrading activity, but a much lower
Vmax for cGMP, making it a cGMP-inhibited cAMP-specific
phosphodiesterase (Fischmeister et al. 2006). In failing rat
heart an enhancing effect of cGMP, generated by activation
of pGC with CNP, on β-adrenergic and 5-HT4 receptor-
mediated inotropic responses has been reported, presumably
through inhibition of PDE3 (Qvigstad et al. 2010; Afzal et al.
2011). In contrast to that, we showed before that CNP alone
does not have an effect on the 5-HT-induced inotropic response
Fig. 4 Effect of particulate guanylyl cyclase stimulation with C-type
natriuretic peptide (CNP, 0.3 μM) 2 and 30 min after administration
and soluble guanylyl cyclase stimulation using the NO-donor Sin-1
(300 μM) 30 min after administration on tissue cGMP content (in
picomole cGMP per milligram protein), in n=4 (CNP 30′) and n=6
(CNP 2′, Sin-1 30′) electrically paced porcine left atrial pectinate
muscles. *P<0.05 versus basal cGMP content, unpaired t test
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in porcine atrium. However, in the presence of PDE4 and
PDE2 inhibition, CNP significantly prolonged the inotropic
response to 5-HT (Weninger et al. 2012). We proposed that
increases in cGMP, mediated by pGC stimulation and further
enhanced by inhibition of its breakdown through PDE2, inhibit
PDE3. Since PDE3 and PDE4 work in a redundant way in
porcine atrium, it was required to inhibit PDE4 as well in order
to unravel an inotropic effect. In the actual study, we show that
the functional response to 5-HTwas significantly larger in the
presence of concurrent CNP plus rolipram, compared to 5-HT
alone, and tended to be larger than the response to 5-HT in the
presence of rolipram. We did not detect an additional effect of
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PLB total
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Fig. 5 Effect of particulate guanylyl cyclase stimulation using C-type
natriuretic peptide (CNP, 0.3 μM) on basal muscle responses and on
responses to 5-HT (1 μM). Measured were force of contraction (a),
tissue cAMP content (b), phosphorylation of phospholamban (c) and
phosphorylation of troponin I (d) of n=11 (a), n=6 (b) and n=5 (c, d)
electrically paced porcine left atrial pectinate muscles. On the x-axis,
the different conditions are plotted; basal values were taken before
addition of any compounds; CNP 2′ and CNP+R 2′ show the own
effect of CNP and CNP administered together with rolipram (1 μM)
after 2 min, respectively. Responses to 5-HT were evaluated at 10 min
after its administration in the absence (5-HT) or presence of rolipram
(R 5-HT), concomitant rolipram plus CNP (R+CNP 5-HT) and
rolipram plus CNP plus EHNA (10 μM; R+CNP+EHNA 5-HT).
Functional responses were calculated as force increase in percentage
to basal force (a), cAMP content is shown as picomole cAMP per
milligram protein (b) and phosphorylation of phospholamban (c) and
troponin I (d) is expressed relative to the household protein β-tubulin
[representative western blots are inserted in panels c and d showing
phosphorylated protein (PLB Ser16, TnI Ser23,24) and total protein
(PLB total, TnI total)]. *P<0.05 versus basal, unpaired t test; ΔP<
0.05 versus 5-HT 10′, one-way ANOVA with Bonferroni post-testing
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PDE2 inhibition with EHNA (Fig. 5a). In line with this, PLB
phosphorylation levels in response to 5-HTwere also increased
to the same extent by both combinations (CNP plus rolipram,
CNP plus rolipram plus EHNA); this level of PLB phosphor-
ylation was significantly higher thanwith 5-HTalone (Fig. 5c).
This supports the assumption that cGMP elevated through
CNP partially inhibits PDE3, which together with PDE4 inhi-
bition considerably slows down cAMP degradation, mediating
the prolonged inotropic response to 5-HT. As for the cAMP
levels, a significantly different result compared to 5-HT alone
was only obtained in the presence of the triple combination
CNP plus rolipram plus EHNA, again suggesting that PDE2
inhibition might be required to fully obtain inhibition of PDE3
with CNP. sGC stimulation using the NO-donor Sin-1 has-
tened the fade of the response to 5-HT4 receptor stimulation in
porcine atrium in this study and previously (Weninger et al.
2012; Fig. 6c). This is in contrast to a study in rat failing
ventricle where Sin-1 increased 5-HT4 receptor-mediated ino-
tropic responses, presumably by inhibition of PDE3 (Afzal et
al. 2011). However, β1-adrenergic receptor signalling in
healthy and failing rat heart was attenuated by Sin-1, the
proposed mechanism being a PKG-mediated inhibition of
L-type Ca2+ channels (Ebihara and Karmazyn 1996; Wang et
al. 2009; Afzal et al. 2011). Preliminary experiments with the
L-type Ca2+ channel blocker verapamil suggest that L-type
Ca2+ channels are not the main mechanism by which Sin-1
decreases responses to 5-HT in pig left atrium. Changes in
cAMP are not involved in the effect of Sin-1 because tissue
cAMP content in response to 5-HT was the same in the
presence of the NO-donor as in its absence (Fig. 6d). Sin-1
simultaneously generates NO and superoxide anion (O2
−)
which react at an almost diffusion-limited rate to peroxynitrite
(ONOO−; Pacher et al. 2007). Peroxynitrite has been shown to
depress contractility in perfused rat hearts by lowering the Ca2+
sensitivity of the contractile apparatus (Schulz et al. 1997;
Brunner and Wolkart 2003). In murine cardiomyocytes,
β-AR responses were reduced by a high concentration of
Sin-1 (200 μM), which was attributed to a peroxynitrite-
mediated increased dephosphorylation of PLB by protein
phosphatase 1 (PP1; Kohr et al. 2008a, b). We suggest that
the effect of 300 μM Sin-1 in pig left atrium might also be
mediated by peroxynitrite as opposed to NO. This is supported
by the fact that SNAP (100 μM), an NO-donor which does not
release O2
−, had no effect on basal nor on 5-HT4 receptor-
mediated responses in a previous study performed in pig
atrium (Weninger et al. 2012). Our data point towards a com-
partmentation of signalling maintained by the action of PDE3
and PDE4, where the cAMP pool in the vicinity of the 5-HT4
5-HTSin-1
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Fig. 6 Effect of soluble guanylyl cyclase stimulation using the NO-
donor Sin-1 (300 μM) on responses to 5-HT (1 μM). Displayed are
representative traces showing responses to 5-HT alone (a) or 5-HT in
the presence of Sin-1 (b) as well as graphs showing mean force of
contraction (c) and tissue cAMP content (d) of n=6 (c, d) electrically
paced porcine left atrial pectinate muscles. On the x-axis of the graphs, the
different conditions are plotted; basal values were taken before addition of
any compounds; Sin-1 values were taken 30min after addition of the NO-
donor; the other bars show responses to 5-HT 2 min (2′) and 10 min (10′)
after its administration in the absence (5-HT) or presence of the NO-donor
(Sin-1 5-HT). Functional responses were calculated as force increase or
decrease in percentage to basal force (c) and cAMP content is shown as
picomole cAMP per milligram protein (d). *P<0.05 versus basal, un-
paired t test
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receptor is not accessible to cGMP generated by sGC, while it
is accessible to cGMP generated by pGC.
Conclusions
We showed that in pig left atrium, PDE3 and PDE4
subtypes are responsible for the fade of the inotropic
response to 5-HT4 receptor activation by controlling the
generation of cAMP and the downstream phosphoryla-
tion of PLB and TnI. Opposed to inotropic responses,
lusitropic responses to 5-HT4 receptor stimulation do not
fade, suggesting that they are less sensitive to PDE
regulation. Generation of cGMP by pGC and sGC acti-
vation differentially influences basal muscle responses
and the inotropic response to 5-HT. Elevated cGMP by
pGC leads to increased cAMP, PLB phosphorylation and
inotropic responses to 5-HT provided PDE4 is inhibited.
In contrast, the negative inotropic responses caused by
Sin-1 are cAMP independent; the mechanism remains to
be elucidated.
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